TY - JOUR
T1 - Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests
AU - Rijken, Dick
AU - Kock, EL (E.)
AU - Guimaraes, AHC
AU - Talens, Simone
AU - Darwish Murad, Sarwa
AU - Janssen, HLA
PY - 2012
Y1 - 2012
N2 - Rijken DC, Kock EL, Guimaraes AHC, Talens S, Murad S Darwish, Janssen HLA, Leebeek FWG. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 211622. Summary. Background and objectives: It has been known for a long time that cirrhosis is associated with hyperfibrinolysis, which might contribute to an increased risk and severity of bleeding. However, recent papers have questioned the presence of a hyperfibrinolytic state in cirrhotic patients and postulated a rebalanced system owing to concomitant changes in both pro- and anti-fibrinolytic factors. Therefore we re-investigated the fibrinolytic state of cirrhotic patients using two different overall tests including a recently developed test for global fibrinolytic capacity (GFC) using whole blood. Patients and methods: Blood was collected from 30 healthy controls and 75 patients with cirrhosis of varying severity (34 ChildPugh A, 28 ChildPugh B and 13 ChildPugh C). The plasma clot lysis time (CLT), which is inversely correlated with fibrinolysis, was determined as well as the GFC. Results: The mean CLT was 74.5 min in the controls and decreased significantly to 66.9 min in ChildPugh class A patients, 59.3 min in class B patients and 61.0 min in class C patients, and hyperfibrinolysis existed in 40% of the patients. The median GFC was 1.7 mu g mL-1 in the controls and increased significantly to 4.0 mu g mL-1 in ChildPugh class A patients, 11.1 mu g mL-1 in class B patients and 22.5 mu g mL-1 in class C patients, and hyperfibrinolysis existed in 43% of the patients. Taken together, 60% of the patients showed hyperfibrinolysis in at least one of the two global assays. Conclusion: A rebalanced fibrinolytic system may occur, but hyperfibrinolysis is found in the majority of patients with cirrhosis.
AB - Rijken DC, Kock EL, Guimaraes AHC, Talens S, Murad S Darwish, Janssen HLA, Leebeek FWG. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 211622. Summary. Background and objectives: It has been known for a long time that cirrhosis is associated with hyperfibrinolysis, which might contribute to an increased risk and severity of bleeding. However, recent papers have questioned the presence of a hyperfibrinolytic state in cirrhotic patients and postulated a rebalanced system owing to concomitant changes in both pro- and anti-fibrinolytic factors. Therefore we re-investigated the fibrinolytic state of cirrhotic patients using two different overall tests including a recently developed test for global fibrinolytic capacity (GFC) using whole blood. Patients and methods: Blood was collected from 30 healthy controls and 75 patients with cirrhosis of varying severity (34 ChildPugh A, 28 ChildPugh B and 13 ChildPugh C). The plasma clot lysis time (CLT), which is inversely correlated with fibrinolysis, was determined as well as the GFC. Results: The mean CLT was 74.5 min in the controls and decreased significantly to 66.9 min in ChildPugh class A patients, 59.3 min in class B patients and 61.0 min in class C patients, and hyperfibrinolysis existed in 40% of the patients. The median GFC was 1.7 mu g mL-1 in the controls and increased significantly to 4.0 mu g mL-1 in ChildPugh class A patients, 11.1 mu g mL-1 in class B patients and 22.5 mu g mL-1 in class C patients, and hyperfibrinolysis existed in 43% of the patients. Taken together, 60% of the patients showed hyperfibrinolysis in at least one of the two global assays. Conclusion: A rebalanced fibrinolytic system may occur, but hyperfibrinolysis is found in the majority of patients with cirrhosis.
U2 - 10.1111/j.1538-7836.2012.04901.x
DO - 10.1111/j.1538-7836.2012.04901.x
M3 - Article
C2 - 22906184
SN - 1538-7933
VL - 10
SP - 2116
EP - 2122
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 10
ER -